<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02535299</url>
  </required_header>
  <id_info>
    <org_study_id>GLP-1</org_study_id>
    <nct_id>NCT02535299</nct_id>
  </id_info>
  <brief_title>Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment</brief_title>
  <acronym>Par-4；GLP-1</acronym>
  <official_title>The Correlation Between Par-4 and Telomere-telomerase System in the New Dignosised Type 2 Diabetes Patients Who Received GLP-1 Analog or Metformin Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To investigate the treatment effect between insulin,metformin and Liraglutide; in
      Type 2 Diabetes in our hospital, in order to investigate the possible mechanism about
      telomere-telomerase system and Par-4.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      160 Type 2 diabetes in our hospital will divide into 4 groups: group A (40 healthy
      volunteers), group B (40 patients who give basal and insulin treatment, group C（40 patients
      who give basal and Liraglutide treatment),group D（40 patients who give basal and metformin
      treatment). The age, height, weight, blood glucose, glycosylated hemoglobin
      A1c（HbA1c）,homeostasis model assessment(HOMA-IR), lipid, blood pressure, course of disease,
      telomere length,telomerase activity will record respectively. And High-sensitive C-reactive
      protein (HsCRP), Par-4, GST,SOD,GSH-PX,ATF-6,CHOP,XBP-1 and Tumor necrosis factor-α（TNF-α）
      will detect as Baseline. After each group's treatment, Change from baseline of all indexes
      will record, Multifactor logistic regression will be analyzed the correlations between each
      positive indexes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>physiological parameter:glycosylated hemoglobin A1c</measure>
    <time_frame>up to 6 months;</time_frame>
    <description>up to 6 months;;HbA1c was measured by a certified hospital laboratory according to established and approved protocols</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>physiological parameter:the concentration of Par-4</measure>
    <time_frame>up to 6 months;</time_frame>
    <description>up to 6 months;;secretary Par-4 were detected with Par-4 ELISA kit (MBL, USA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physiological parameter:telomere length</measure>
    <time_frame>up to 6 months;</time_frame>
    <description>up to 6 months;;Telomere length was measured via fluorescence in situ hybridization using flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physiological parameter:telomease activity</measure>
    <time_frame>up to 6 months;</time_frame>
    <description>up to 6 months;;Telomerase activity was measured using the TeloTAGGG Telomerase PCR ELISAPLUS kit (Roche Diagnostics, Mannheim, Germany)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physiological parameter:TNF-α</measure>
    <time_frame>up to 6 months;</time_frame>
    <description>up to 6 months, TNF-a levels were measured by commercial ELISA kit following the manufacturer's instructions;TNF-a levels were measured by commercial ELISA kit following the manufacturer's instructions;(MBL, USA)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>GLP-1；Metformin；Telomere-telomerase System；Par-4</condition>
  <arm_group>
    <arm_group_label>insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>basic insulin treatment：glargine 10-30 units once a day based on the glucose control for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months</description>
    <arm_group_label>insulin</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin(1500mg-2000mg/day) treatment for 6 months</description>
    <arm_group_label>insulin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly dignosised type 2 diabetes according to WHO criteria.glycated hemoglobin (HbA1c)
             was more than 10%;

          -  Seronegative for antibodies against insulin, islet cells and glutamic acid
             decarboxylase (GAD);

        Exclusion Criteria:

          -  Type 1 diabetes mellitus,presence of autoimmune diabetes indicated by antibodies to
             insulin, islet cells, and GAD；

          -  Gestational diabetes;

          -  patients with heart, liver, or renal function impairment;presence of severe infections
             or cerebrovascular disease;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southwest Hospital of the Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wu qi nan, doctor</last_name>
      <phone>13452867542</phone>
      <phone_ext>+86</phone_ext>
      <email>wqn11@126.com</email>
    </contact>
    <contact_backup>
      <last_name>chen bing, doctor</last_name>
      <phone>68754138</phone>
      <phone_ext>+86</phone_ext>
      <email>chenbing3@medmail.com.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <last_update_submitted>September 10, 2016</last_update_submitted>
  <last_update_submitted_qc>September 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Wu Qinan</investigator_full_name>
    <investigator_title>the Third Military Medical University</investigator_title>
  </responsible_party>
  <keyword>telomere-telomerase</keyword>
  <keyword>Par-4</keyword>
  <keyword>GLP-1</keyword>
  <keyword>metformin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

